Prescient Therapeutics: Shareholder Briefing with CEO James McDonnell
CEO James McDonnell, held a shareholder briefing with Reach Markets.
In this session, James discussed:
- What to expect from our Phase 2a trial, with First Patient In and Dosed (FPID) anticipated in the coming weeks.
- How our promising Phase 1b results could help turn our Phase 2 trial into a registrational study.
- The significance of the Fast Track Designation granted by the FDA in April, and what it means for our potential accelerated path to commercialisation.
Recorded on 21st May 2025 at 1pm (AEST)
Featured Speaker
James McDonnell
CEO
James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.
Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing to the company’s acquistion by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.
James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.
